?? In case you missed it, our joint blog post on the AWS Architecture Blog is creating a buzz! One of the most read posts to date in 2025, the article details how Clario's custom generative AI platform on Amazon Web Services (AWS) is transforming?the process of extracting insights from complex clinical documents. Explore the full story and learn more about how we’re transforming clinical trial document analysis ?? https://lnkd.in/ef9BF5Uu We’re also proud to highlight Alex Boudreau's leadership in driving this innovation, as he shares his expertise in the AWS Healthcare & Life Sciences Boston Customer Meetup on April 17, 2025, from 3:00 pm to 5:30 pm ET. ?? Save your seat for the virtual session here: https://lnkd.in/eK2MYmyz #ClinicalTrials #ClarioAI #ResponsibleAI
Clario
生物技术研究
Philadelphia，Pennsylvania 111,925 位关注者
Transforming Lives by Unlocking Better Evidence | Decentralized clinical trials | Broadest endpoint technology
关于我们
Clario is a leading healthcare research and technology company that generates high quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Since our founding more than 50 years ago, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported clinical trials over 26,000 times in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2019. For more information, visit Clario.com
- 网站
-
https://clario.com/
Clario的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Philadelphia，Pennsylvania
- 类型
- 私人持股
- 创立
- 1972
- 领域
- Cardiac Solutions、Medical Imaging、eCOA、Respiratory Solutions、Precision Motion、Specialty Solutions、Clinical Adjudication和Artificial Intelligence
地点
Clario员工
动态
-
We are delighted to welcome this brilliant team to the Clario family! ? #NeuroRx #ClarioImaging #ClarioNeuroscience
Great visit with our NeuroRx Team in Montreal last week. The combining of our super-talented teams is very exciting and I look forward to seeing what we will accomplish together (and to practicing my French). Read our full press release: https://lnkd.in/e68jcVRQ #NeuroRx #ClarioImaging #ClarioNeuroscience #MultipleSclerosisResearch
-
-
Clario's VP of Medical & Scientific Affairs for Precision Motion, Kristen Sowalsky, PhD, DC, recently participated in a panel discussion at HIMSS Global Health Conference & Exhibition. The session, Revolutionizing Drug Development Through Strategic and Evidence-Driven Digital Health Innovations, focused on how digital health technologies (DHTs) are transforming drug development by improving?motor symptom detection, go/no-go decisions, and real-world evidence collection. Cheers to the panel for an insightful collaboration! Explore Clario's complete solution for measuring digital endpoints of mobility: https://lnkd.in/eFzcnhAY
It was a pleasure to join Sakshi S., Fatta B. Nahab MD, FAAN, FANA, and Jaydev Thakkar in a panel discussion on Revolutionizing Drug Development Through Strategic and Evidence-Driven Digital Health Innovations at the HIMSS Global Health Conference & Exhibition this year. Grateful for the wonderful collaboration between the Critical Path Institute (C-Path), Neuron23, ActiGraph, and Clario.
-
-
?? Don't miss tomorrow's webinar! ? Join us at 11:00 AM ET for an insightful roundtable on the evolving AI regulatory landscape and its impact on clinical trials. ? What you'll learn:? ?? Key updates from the EU AI Act and FDA's latest AI guidance? ?? Regulatory considerations around fairness, data privacy, safety, and model transparency? ?? Practical strategies for integrating AI technologies into clinical trial workflows ? This is a great opportunity to stay informed and gain valuable insights for your clinical trials. Register now to secure your spot: https://lnkd.in/eshWTz4Y #ClinicalTrials #ResponsibleAI #ClarioAI
-
Attending AD/PD 2025? We have lots to share with you!? ? ?? Stop by Clario's booth #50 to find out how we can transform your neuroscience clinical trials with high-quality digital endpoint solutions. And don't miss our poster sessions:? ? Poster 1: Opal sensor equivalency to capture Mobilise-D digital mobility outcomes? Presented by Kristen Sowalsky, PhD, DC, VP, Product Management & Scientific Affairs, Precision Motion? ? Poster 2: Breaking boundaries: How digital movement endpoints outperform clinical scales in tracking disease progression in people with Parkinson’s disease? Presented by Vrutangkumar Shah, Ph.D., Director, Data Science and Biostatistics, Precision Motion? ? Find more event information here: https://lnkd.in/espNUBvz? ? #ADPD2025 #Neuroscience #ClinicalTrials?
-
-
If you missed our LinkedIn Live event discussing the FDA's latest draft guidance on weight-management drugs, the recording is now available!? ? Watch it now to catch up as our experts explore:? ? Key messages from the FDA’s draft guidance for obesity drug development? ? The evolving role of clinical outcome assessments (COAs) and how they can impact labeling claims? ? Practical tips for sponsors on adapting clinical trial design? ? Learn more about the key takeaways and how a comprehensive endpoint strategy can help fulfil regulatory expectations for development of obesity treatments in our article by Todd Rudo, M.D. and Paul Strumph, M.D.: https://lnkd.in/e2b4bwDA
?? The FDA’s new draft guidance for obesity drug development introduces important recommendations that will shape the future of clinical trials in this rapidly expanding market. With the obesity drug market projected to hit $100 billion by 2030, maintaining awareness of the evolving regulatory landscape is crucial for success. ? Join us on March 13 at 10 am ET for an exclusive LinkedIn Live discussion with Todd Rudo, M.D., and Paul Strumph, M.D., as they walk through the key takeaways from the FDA’s new draft guidance. They will discuss its impact on clinical trial design, safety and efficacy endpoints, and regulatory strategy. ? Topics will include: ? Key messages in the FDA guidelines for evaluating weight-management drugs ? The critical role of COAs in supporting labelling claims ? How to navigate regulatory expectations and stay competitive in this fast-growing field RSVP now to join us live and get the insights you need to navigate the changing regulatory landscape. ??
Navigating the FDA’s New Draft Guidance for Obesity Clinical Trials
www.dhirubhai.net
-
?? Exciting news!? Clario announces the acquisition of NeuroRx, a leader in imaging analysis with expertise in neuroscience. "By augmenting our expertise in this critical therapeutic area," says Clario CEO, Christopher Fikry, M.D., "We are even better positioned to support our customers in developing life-changing drugs.” ? ? Read the full press release: https://lnkd.in/e68jcVRQ
-
-
?? The FDA’s new draft guidance for obesity drug development introduces important recommendations that will shape the future of clinical trials in this rapidly expanding market. With the obesity drug market projected to hit $100 billion by 2030, maintaining awareness of the evolving regulatory landscape is crucial for success. ? Join us on March 13 at 10 am ET for an exclusive LinkedIn Live discussion with Todd Rudo, M.D., and Paul Strumph, M.D., as they walk through the key takeaways from the FDA’s new draft guidance. They will discuss its impact on clinical trial design, safety and efficacy endpoints, and regulatory strategy. ? Topics will include: ? Key messages in the FDA guidelines for evaluating weight-management drugs ? The critical role of COAs in supporting labelling claims ? How to navigate regulatory expectations and stay competitive in this fast-growing field RSVP now to join us live and get the insights you need to navigate the changing regulatory landscape. ??
Navigating the FDA’s New Draft Guidance for Obesity Clinical Trials
www.dhirubhai.net
-
? Our LinkedIn Live event, “Navigating the FDA’s New Draft Guidance for Obesity Clinical Trials,” is one day away. This is your chance to get the inside scoop on the latest regulatory updates shaping the future of obesity drug development. Don't miss this engaging session with our experts Todd Rudo, M.D., Chief Medical Officer, and Paul Strumph, M.D., Diabetes & Metabolism Key Opinion Leader. Save your spot and join us tomorrow at 10:00am ET! ??
?? The FDA’s new draft guidance for obesity drug development introduces important recommendations that will shape the future of clinical trials in this rapidly expanding market. With the obesity drug market projected to hit $100 billion by 2030, maintaining awareness of the evolving regulatory landscape is crucial for success. ? Join us on March 13 at 10 am ET for an exclusive LinkedIn Live discussion with Todd Rudo, M.D., and Paul Strumph, M.D., as they walk through the key takeaways from the FDA’s new draft guidance. They will discuss its impact on clinical trial design, safety and efficacy endpoints, and regulatory strategy. ? Topics will include: ? Key messages in the FDA guidelines for evaluating weight-management drugs ? The critical role of COAs in supporting labelling claims ? How to navigate regulatory expectations and stay competitive in this fast-growing field RSVP now to join us live and get the insights you need to navigate the changing regulatory landscape. ??
Navigating the FDA’s New Draft Guidance for Obesity Clinical Trials
www.dhirubhai.net
-
In a time of increasing complexity in clinical trials, regulatory bodies require more than just robust data—they need consistency, accuracy, and an unbiased evaluation. An independent clinical adjudication process plays a critical role in ensuring endpoint assessments meet these high demands, reducing variability and strengthening the credibility of trial results. ? At Clario, we recognize adjudication not just as helping to comply, but as a strategic advantage. A well-designed adjudication process and robust platform can de-risk regulatory submissions, enhance data integrity, and help accelerate approvals—ultimately bringing life-changing treatments to patients sooner. ? Explore how clinical adjudication can transform trial outcomes: https://lnkd.in/e422vFGA #ClinicalTrials #ClinicalAdjudication
-